JP2010536757A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010536757A5 JP2010536757A5 JP2010521039A JP2010521039A JP2010536757A5 JP 2010536757 A5 JP2010536757 A5 JP 2010536757A5 JP 2010521039 A JP2010521039 A JP 2010521039A JP 2010521039 A JP2010521039 A JP 2010521039A JP 2010536757 A5 JP2010536757 A5 JP 2010536757A5
- Authority
- JP
- Japan
- Prior art keywords
- piperazin
- imidazo
- pyridin
- compound according
- methanone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 124
- 238000000034 method Methods 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 29
- -1 C 1 -C 6 alkylureyl Chemical group 0.000 claims description 27
- 229910052736 halogen Inorganic materials 0.000 claims description 26
- 150000002367 halogens Chemical class 0.000 claims description 26
- 150000004677 hydrates Chemical class 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 22
- 239000012453 solvate Substances 0.000 claims description 22
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 18
- 208000019116 sleep disease Diseases 0.000 claims description 17
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 16
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 150000003857 carboxamides Chemical class 0.000 claims description 12
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 10
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 10
- 230000007958 sleep Effects 0.000 claims description 10
- 208000020685 sleep-wake disease Diseases 0.000 claims description 9
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 8
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 125000001246 bromo group Chemical group Br* 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 206010022437 insomnia Diseases 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 230000037322 slow-wave sleep Effects 0.000 claims description 6
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 6
- 229940124530 sulfonamide Drugs 0.000 claims description 6
- 150000003456 sulfonamides Chemical class 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000004617 sleep duration Effects 0.000 claims description 5
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims description 4
- 125000004741 (C1-C6) haloalkylsulfonyl group Chemical group 0.000 claims description 4
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 208000006199 Parasomnias Diseases 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 125000005432 dialkylcarboxamide group Chemical group 0.000 claims description 4
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 4
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
- WHQVCDFJOLJQNH-UHFFFAOYSA-N (2-tert-butylimidazo[1,2-a]pyridin-8-yl)-[4-[2-(4-fluorophenyl)ethyl]piperazin-1-yl]methanone Chemical compound C12=NC(C(C)(C)C)=CN2C=CC=C1C(=O)N(CC1)CCN1CCC1=CC=C(F)C=C1 WHQVCDFJOLJQNH-UHFFFAOYSA-N 0.000 claims description 3
- GJRMSGRAWMZMDU-UHFFFAOYSA-N (3-bromoimidazo[1,2-a]pyridin-8-yl)-[4-[2-(2,4-difluorophenyl)ethyl]piperazin-1-yl]methanone Chemical compound FC1=CC(F)=CC=C1CCN1CCN(C(=O)C=2C3=NC=C(Br)N3C=CC=2)CC1 GJRMSGRAWMZMDU-UHFFFAOYSA-N 0.000 claims description 3
- FRYOPPXAFLGFOG-UHFFFAOYSA-N (3-chloroimidazo[1,2-a]pyridin-8-yl)-[4-[2-(2,4-difluorophenyl)ethyl]piperazin-1-yl]methanone Chemical compound FC1=CC(F)=CC=C1CCN1CCN(C(=O)C=2C3=NC=C(Cl)N3C=CC=2)CC1 FRYOPPXAFLGFOG-UHFFFAOYSA-N 0.000 claims description 3
- CGLUZTJNYKGOLE-UHFFFAOYSA-N (6-bromoimidazo[1,2-a]pyridin-8-yl)-[4-[2-(2,4-difluorophenyl)ethyl]piperazin-1-yl]methanone Chemical compound FC1=CC(F)=CC=C1CCN1CCN(C(=O)C=2C3=NC=CN3C=C(Br)C=2)CC1 CGLUZTJNYKGOLE-UHFFFAOYSA-N 0.000 claims description 3
- PENJSKTXKZICAN-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-[4-(imidazo[1,2-a]pyridine-8-carbonyl)piperazin-1-yl]ethanone Chemical compound C1=CC(F)=CC=C1C(=O)CN1CCN(C(=O)C=2C3=NC=CN3C=CC=2)CC1 PENJSKTXKZICAN-UHFFFAOYSA-N 0.000 claims description 3
- YJQBYPWNRLDKAP-UHFFFAOYSA-N 8-[4-[2-(2,4-difluorophenyl)ethyl]piperazine-1-carbonyl]imidazo[1,2-a]pyridine-3-carbonitrile Chemical compound FC1=CC(F)=CC=C1CCN1CCN(C(=O)C=2C3=NC=C(N3C=CC=2)C#N)CC1 YJQBYPWNRLDKAP-UHFFFAOYSA-N 0.000 claims description 3
- VZVRPAJUWQVLAH-UHFFFAOYSA-N [4-[2-(2,4-dichlorophenyl)ethyl]piperazin-1-yl]-imidazo[1,2-a]pyridin-8-ylmethanone Chemical compound ClC1=CC(Cl)=CC=C1CCN1CCN(C(=O)C=2C3=NC=CN3C=CC=2)CC1 VZVRPAJUWQVLAH-UHFFFAOYSA-N 0.000 claims description 3
- FRKLMSCCEDKZGG-UHFFFAOYSA-N [4-[2-(2,4-difluorophenyl)ethyl]piperazin-1-yl]-(5,7-dimethylimidazo[1,2-a]pyridin-8-yl)methanone Chemical compound CC=1C=C(C)N2C=CN=C2C=1C(=O)N(CC1)CCN1CCC1=CC=C(F)C=C1F FRKLMSCCEDKZGG-UHFFFAOYSA-N 0.000 claims description 3
- USTBGZUJKCBYAR-UHFFFAOYSA-N [4-[2-(2,4-difluorophenyl)ethyl]piperazin-1-yl]-imidazo[1,2-a]pyridin-8-ylmethanone Chemical compound FC1=CC(F)=CC=C1CCN1CCN(C(=O)C=2C3=NC=CN3C=CC=2)CC1 USTBGZUJKCBYAR-UHFFFAOYSA-N 0.000 claims description 3
- HBMDPQCWADWQKX-UHFFFAOYSA-N [4-[2-(4-fluorophenyl)ethyl]piperazin-1-yl]-imidazo[1,2-a]pyridin-8-ylmethanone Chemical compound C1=CC(F)=CC=C1CCN1CCN(C(=O)C=2C3=NC=CN3C=CC=2)CC1 HBMDPQCWADWQKX-UHFFFAOYSA-N 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- SZSUIOUUZUDBAH-UHFFFAOYSA-N 1-(2,4-difluorophenyl)-2-[4-(imidazo[1,2-a]pyridine-8-carbonyl)piperazin-1-yl]ethanone Chemical compound FC1=CC(F)=CC=C1C(=O)CN1CCN(C(=O)C=2C3=NC=CN3C=CC=2)CC1 SZSUIOUUZUDBAH-UHFFFAOYSA-N 0.000 claims description 2
- LCDXLCXXQFHNKV-UHFFFAOYSA-N 1-(4-chloro-2-fluoro-5-methylphenyl)-2-[4-(imidazo[1,2-a]pyridine-8-carbonyl)piperazin-1-yl]ethanone Chemical compound C1=C(Cl)C(C)=CC(C(=O)CN2CCN(CC2)C(=O)C=2C3=NC=CN3C=CC=2)=C1F LCDXLCXXQFHNKV-UHFFFAOYSA-N 0.000 claims description 2
- ZDNJCQJVOWYKHC-UHFFFAOYSA-N 1-(4-cyclohexylphenyl)-2-[4-(imidazo[1,2-a]pyridine-8-carbonyl)piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C=2C3=NC=CN3C=CC=2)CCN1CC(=O)C(C=C1)=CC=C1C1CCCCC1 ZDNJCQJVOWYKHC-UHFFFAOYSA-N 0.000 claims description 2
- YOLJECWHMSPAJR-UHFFFAOYSA-N 1-(4-hydroxyphenyl)-2-[4-(imidazo[1,2-a]pyridine-8-carbonyl)piperazin-1-yl]ethanone Chemical compound C1=CC(O)=CC=C1C(=O)CN1CCN(C(=O)C=2C3=NC=CN3C=CC=2)CC1 YOLJECWHMSPAJR-UHFFFAOYSA-N 0.000 claims description 2
- ABHYANHOWXLJLE-UHFFFAOYSA-N 1-(5-chloro-2-methoxy-4-methyl-3-nitrophenyl)-2-[4-(imidazo[1,2-a]pyridine-8-carbonyl)piperazin-1-yl]ethanone Chemical compound C1=C(Cl)C(C)=C([N+]([O-])=O)C(OC)=C1C(=O)CN1CCN(C(=O)C=2C3=NC=CN3C=CC=2)CC1 ABHYANHOWXLJLE-UHFFFAOYSA-N 0.000 claims description 2
- BFUCCJOIGPOJED-UHFFFAOYSA-N 1-(5-chloro-2-methoxy-4-methylphenyl)-2-[4-(imidazo[1,2-a]pyridine-8-carbonyl)piperazin-1-yl]ethanone Chemical compound COC1=CC(C)=C(Cl)C=C1C(=O)CN1CCN(C(=O)C=2C3=NC=CN3C=CC=2)CC1 BFUCCJOIGPOJED-UHFFFAOYSA-N 0.000 claims description 2
- LWHDYZCJFAAYMD-UHFFFAOYSA-N 1-[2-chloro-5-(trifluoromethyl)phenyl]-2-[4-(imidazo[1,2-a]pyridine-8-carbonyl)piperazin-1-yl]ethanone Chemical compound FC(F)(F)C1=CC=C(Cl)C(C(=O)CN2CCN(CC2)C(=O)C=2C3=NC=CN3C=CC=2)=C1 LWHDYZCJFAAYMD-UHFFFAOYSA-N 0.000 claims description 2
- YIZGIAFLSCLGEH-UHFFFAOYSA-N 1-[3,5-bis(trifluoromethyl)phenyl]-2-[4-(imidazo[1,2-a]pyridine-8-carbonyl)piperazin-1-yl]ethanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)CN2CCN(CC2)C(=O)C=2C3=NC=CN3C=CC=2)=C1 YIZGIAFLSCLGEH-UHFFFAOYSA-N 0.000 claims description 2
- IZMXHVJGCGIJOR-UHFFFAOYSA-N 1-[4-(difluoromethoxy)phenyl]-2-[4-(imidazo[1,2-a]pyridine-8-carbonyl)piperazin-1-yl]ethanone Chemical compound C1=CC(OC(F)F)=CC=C1C(=O)CN1CCN(C(=O)C=2C3=NC=CN3C=CC=2)CC1 IZMXHVJGCGIJOR-UHFFFAOYSA-N 0.000 claims description 2
- CYKOHDBHTLVXES-UHFFFAOYSA-N 1-[4-(dimethylamino)phenyl]-2-[4-(imidazo[1,2-a]pyridine-8-carbonyl)piperazin-1-yl]ethanone Chemical compound C1=CC(N(C)C)=CC=C1C(=O)CN1CCN(C(=O)C=2C3=NC=CN3C=CC=2)CC1 CYKOHDBHTLVXES-UHFFFAOYSA-N 0.000 claims description 2
- JFKLZKHLHNSEPL-UHFFFAOYSA-N 2-[4-(imidazo[1,2-a]pyridine-8-carbonyl)piperazin-1-yl]-1-(4-methylsulfonylphenyl)ethanone Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(=O)CN1CCN(C(=O)C=2C3=NC=CN3C=CC=2)CC1 JFKLZKHLHNSEPL-UHFFFAOYSA-N 0.000 claims description 2
- HDEVBPZBYPORAX-UHFFFAOYSA-N 2-[4-(imidazo[1,2-a]pyridine-8-carbonyl)piperazin-1-yl]-1-(4-morpholin-4-ylphenyl)ethanone Chemical compound C1CN(C(=O)C=2C3=NC=CN3C=CC=2)CCN1CC(=O)C(C=C1)=CC=C1N1CCOCC1 HDEVBPZBYPORAX-UHFFFAOYSA-N 0.000 claims description 2
- FPNLUNIQQWKINM-UHFFFAOYSA-N 2-[4-(imidazo[1,2-a]pyridine-8-carbonyl)piperazin-1-yl]-1-(4-phenylphenyl)ethanone Chemical compound C1CN(C(=O)C=2C3=NC=CN3C=CC=2)CCN1CC(=O)C(C=C1)=CC=C1C1=CC=CC=C1 FPNLUNIQQWKINM-UHFFFAOYSA-N 0.000 claims description 2
- MUJAPMDAVJDNBZ-UHFFFAOYSA-N 2-[4-(imidazo[1,2-a]pyridine-8-carbonyl)piperazin-1-yl]-1-(4-pyrrolidin-1-ylphenyl)ethanone Chemical compound C1CN(C(=O)C=2C3=NC=CN3C=CC=2)CCN1CC(=O)C(C=C1)=CC=C1N1CCCC1 MUJAPMDAVJDNBZ-UHFFFAOYSA-N 0.000 claims description 2
- YEAMDHONLJCKAM-UHFFFAOYSA-N 2-[4-(imidazo[1,2-a]pyridine-8-carbonyl)piperazin-1-yl]-1-[2-(trifluoromethyl)phenyl]ethanone Chemical compound FC(F)(F)C1=CC=CC=C1C(=O)CN1CCN(C(=O)C=2C3=NC=CN3C=CC=2)CC1 YEAMDHONLJCKAM-UHFFFAOYSA-N 0.000 claims description 2
- FDBIDDUKSXCSHM-UHFFFAOYSA-N 2-[4-(imidazo[1,2-a]pyridine-8-carbonyl)piperazin-1-yl]-1-[4-(trifluoromethoxy)phenyl]ethanone Chemical compound C1=CC(OC(F)(F)F)=CC=C1C(=O)CN1CCN(C(=O)C=2C3=NC=CN3C=CC=2)CC1 FDBIDDUKSXCSHM-UHFFFAOYSA-N 0.000 claims description 2
- BBFQNJGJAFYLPB-UHFFFAOYSA-N 2-[4-(imidazo[1,2-a]pyridine-8-carbonyl)piperazin-1-yl]-1-[4-(trifluoromethyl)phenyl]ethanone Chemical compound C1=CC(C(F)(F)F)=CC=C1C(=O)CN1CCN(C(=O)C=2C3=NC=CN3C=CC=2)CC1 BBFQNJGJAFYLPB-UHFFFAOYSA-N 0.000 claims description 2
- DYUVBKZDPPCZJP-UHFFFAOYSA-N 2-[4-(imidazo[1,2-a]pyridine-8-carbonyl)piperazin-1-yl]-1-phenylpropan-1-one Chemical compound C1CN(C(=O)C=2C3=NC=CN3C=CC=2)CCN1C(C)C(=O)C1=CC=CC=C1 DYUVBKZDPPCZJP-UHFFFAOYSA-N 0.000 claims description 2
- WDPHZKMNWUESJZ-UHFFFAOYSA-N 2-hydroxy-5-[2-[4-(imidazo[1,2-a]pyridine-8-carbonyl)piperazin-1-yl]acetyl]benzamide Chemical compound C1=C(O)C(C(=O)N)=CC(C(=O)CN2CCN(CC2)C(=O)C=2C3=NC=CN3C=CC=2)=C1 WDPHZKMNWUESJZ-UHFFFAOYSA-N 0.000 claims description 2
- TWRLNKASBJDRDP-UHFFFAOYSA-N 4-[2-[4-(imidazo[1,2-a]pyridine-8-carbonyl)piperazin-1-yl]acetyl]benzonitrile Chemical compound C1CN(C(=O)C=2C3=NC=CN3C=CC=2)CCN1CC(=O)C1=CC=C(C#N)C=C1 TWRLNKASBJDRDP-UHFFFAOYSA-N 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- HGOYIILQUZWXAD-UHFFFAOYSA-N [4-[2-(2,4-difluorophenyl)ethyl]piperazin-1-yl]-(7-methoxyimidazo[1,2-a]pyridin-8-yl)methanone Chemical compound COC=1C=CN2C=CN=C2C=1C(=O)N(CC1)CCN1CCC1=CC=C(F)C=C1F HGOYIILQUZWXAD-UHFFFAOYSA-N 0.000 claims description 2
- DPMWZOFTOGCSCJ-UHFFFAOYSA-N [4-[2-(2-chlorophenyl)ethyl]piperazin-1-yl]-imidazo[1,2-a]pyridin-8-ylmethanone Chemical compound ClC1=CC=CC=C1CCN1CCN(C(=O)C=2C3=NC=CN3C=CC=2)CC1 DPMWZOFTOGCSCJ-UHFFFAOYSA-N 0.000 claims description 2
- FHHNEEMCBOUXDT-UHFFFAOYSA-N [4-[2-(2-fluorophenyl)ethyl]piperazin-1-yl]-imidazo[1,2-a]pyridin-8-ylmethanone Chemical compound FC1=CC=CC=C1CCN1CCN(C(=O)C=2C3=NC=CN3C=CC=2)CC1 FHHNEEMCBOUXDT-UHFFFAOYSA-N 0.000 claims description 2
- WKBVVBVHZRKBJO-UHFFFAOYSA-N [4-[2-(3,4-dimethoxyphenyl)ethyl]piperazin-1-yl]-imidazo[1,2-a]pyridin-8-ylmethanone Chemical compound C1=C(OC)C(OC)=CC=C1CCN1CCN(C(=O)C=2C3=NC=CN3C=CC=2)CC1 WKBVVBVHZRKBJO-UHFFFAOYSA-N 0.000 claims description 2
- FRBWJJVBHFQPGJ-UHFFFAOYSA-N [4-[2-(3-chlorophenyl)ethyl]piperazin-1-yl]-imidazo[1,2-a]pyridin-8-ylmethanone Chemical compound ClC1=CC=CC(CCN2CCN(CC2)C(=O)C=2C3=NC=CN3C=CC=2)=C1 FRBWJJVBHFQPGJ-UHFFFAOYSA-N 0.000 claims description 2
- PFGWHBRURZXWCM-UHFFFAOYSA-N [4-[2-(3-fluorophenyl)ethyl]piperazin-1-yl]-imidazo[1,2-a]pyridin-8-ylmethanone Chemical compound FC1=CC=CC(CCN2CCN(CC2)C(=O)C=2C3=NC=CN3C=CC=2)=C1 PFGWHBRURZXWCM-UHFFFAOYSA-N 0.000 claims description 2
- LMBRGFFBARBECT-UHFFFAOYSA-N [4-[2-(4-chlorophenyl)ethyl]piperazin-1-yl]-imidazo[1,2-a]pyridin-8-ylmethanone Chemical compound C1=CC(Cl)=CC=C1CCN1CCN(C(=O)C=2C3=NC=CN3C=CC=2)CC1 LMBRGFFBARBECT-UHFFFAOYSA-N 0.000 claims description 2
- OXYLMGLKAKEZBC-UHFFFAOYSA-N [4-[2-(4-fluorophenyl)ethyl]piperazin-1-yl]-(2-methylimidazo[1,2-a]pyridin-8-yl)methanone Chemical compound C12=NC(C)=CN2C=CC=C1C(=O)N(CC1)CCN1CCC1=CC=C(F)C=C1 OXYLMGLKAKEZBC-UHFFFAOYSA-N 0.000 claims description 2
- MBHSPGRNAMMQGA-UHFFFAOYSA-N [4-[2-(4-fluorophenyl)ethyl]piperazin-1-yl]-(2-phenylimidazo[1,2-a]pyridin-8-yl)methanone Chemical compound C1=CC(F)=CC=C1CCN1CCN(C(=O)C=2C3=NC(=CN3C=CC=2)C=2C=CC=CC=2)CC1 MBHSPGRNAMMQGA-UHFFFAOYSA-N 0.000 claims description 2
- HPWPUPUSMGYJFI-UHFFFAOYSA-N [4-[2-(4-fluorophenyl)ethyl]piperazin-1-yl]-[2-(trifluoromethyl)imidazo[1,2-a]pyridin-8-yl]methanone Chemical compound C1=CC(F)=CC=C1CCN1CCN(C(=O)C=2C3=NC(=CN3C=CC=2)C(F)(F)F)CC1 HPWPUPUSMGYJFI-UHFFFAOYSA-N 0.000 claims description 2
- RFQBISKRBWMSHN-UHFFFAOYSA-N [4-[2-fluoro-2-(4-fluorophenyl)ethyl]piperazin-1-yl]-imidazo[1,2-a]pyridin-8-ylmethanone Chemical compound C1CN(C(=O)C=2C3=NC=CN3C=CC=2)CCN1CC(F)C1=CC=C(F)C=C1 RFQBISKRBWMSHN-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 125000005518 carboxamido group Chemical group 0.000 claims description 2
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims description 2
- UXXQRGPDBUYDOW-UHFFFAOYSA-N imidazo[1,2-a]pyridin-8-yl-[4-[2-(4-methoxyphenyl)ethyl]piperazin-1-yl]methanone Chemical compound C1=CC(OC)=CC=C1CCN1CCN(C(=O)C=2C3=NC=CN3C=CC=2)CC1 UXXQRGPDBUYDOW-UHFFFAOYSA-N 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- GKXNRPWUSZOIPY-UHFFFAOYSA-N n-[2-hydroxy-5-[2-[4-(imidazo[1,2-a]pyridine-8-carbonyl)piperazin-1-yl]acetyl]phenyl]methanesulfonamide Chemical compound C1=C(O)C(NS(=O)(=O)C)=CC(C(=O)CN2CCN(CC2)C(=O)C=2C3=NC=CN3C=CC=2)=C1 GKXNRPWUSZOIPY-UHFFFAOYSA-N 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 2
- 150000003457 sulfones Chemical class 0.000 claims description 2
- VZCHCIWHJLPPNF-UHFFFAOYSA-N 1-(4-thiophen-2-ylphenyl)ethanone Chemical compound C1=CC(C(=O)C)=CC=C1C1=CC=CS1 VZCHCIWHJLPPNF-UHFFFAOYSA-N 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 230000002787 reinforcement Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 description 10
- 125000003545 alkoxy group Chemical group 0.000 description 9
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000004423 acyloxy group Chemical group 0.000 description 4
- 125000004422 alkyl sulphonamide group Chemical group 0.000 description 4
- 125000005431 alkyl carboxamide group Chemical group 0.000 description 3
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 2
- LVMDLJZSGYPANL-UHFFFAOYSA-N 2-[4-(imidazo[1,2-a]pyridine-8-carbonyl)piperazin-1-yl]-1-(4-thiophen-2-ylphenyl)ethanone Chemical compound C1CN(C(=O)C=2C3=NC=CN3C=CC=2)CCN1CC(=O)C(C=C1)=CC=C1C1=CC=CS1 LVMDLJZSGYPANL-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96484907P | 2007-08-15 | 2007-08-15 | |
| US60/964,849 | 2007-08-15 | ||
| PCT/US2008/009740 WO2009023253A2 (en) | 2007-08-15 | 2008-08-14 | IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010536757A JP2010536757A (ja) | 2010-12-02 |
| JP2010536757A5 true JP2010536757A5 (enExample) | 2012-09-13 |
| JP5393677B2 JP5393677B2 (ja) | 2014-01-22 |
Family
ID=39828967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010521039A Expired - Fee Related JP5393677B2 (ja) | 2007-08-15 | 2008-08-14 | ５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US9567327B2 (enExample) |
| EP (1) | EP2190844B3 (enExample) |
| JP (1) | JP5393677B2 (enExample) |
| ES (1) | ES2421237T7 (enExample) |
| WO (1) | WO2009023253A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1558582T3 (pl) | 2003-07-22 | 2006-05-31 | Arena Pharm Inc | Diarylowe i aryloheteroarylowe pochodne mocznika jako modulatory receptora serotoninowego 5-HT2A użyteczne w profilaktyce i w leczeniu zaburzeń związanych z tym receptorem |
| SA05260357B1 (ar) | 2004-11-19 | 2008-09-08 | ارينا فارماسيتو تيكالز ، أنك | مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به |
| SG171681A1 (en) | 2006-05-18 | 2011-06-29 | Arena Pharm Inc | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor |
| EP3395816A1 (en) | 2006-05-18 | 2018-10-31 | Arena Pharmaceuticals, Inc. | Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| WO2007136703A1 (en) | 2006-05-18 | 2007-11-29 | Arena Pharmaceuticals, Inc. | Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 |
| ES2421237T7 (es) | 2007-08-15 | 2013-09-30 | Arena Pharmaceuticals, Inc. | Derivados de imidazo[1,2-a]piridin como moduladores del receptor serotoninérgico 5ht2a en el tratamiento de trastornos relacionados con el mismo |
| WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| SMT201800199T1 (it) | 2008-10-28 | 2018-05-02 | Arena Pharm Inc | Composizioni di un modulatore dei recettori della serotonina 5-ht2a utili per il trattamento di disturbi correlati a esso |
| WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
| CA2778949C (en) | 2009-10-30 | 2018-02-27 | Janssen Pharmaceutica Nv | Imidazo[1,2-b]pyridazine derivatives and their use as pde10 inhibitors |
| WO2011075596A1 (en) | 2009-12-18 | 2011-06-23 | Arena Pharmaceuticals, Inc. | Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| EP2569450A4 (en) * | 2010-05-14 | 2013-12-25 | Univ Rochester | Compositions and methods for targeting a3g:rna complexes |
| JP6115962B2 (ja) | 2011-06-27 | 2017-04-19 | ヤンセン ファーマシューティカ エヌ．ベー． | １−アリール−４−メチル−［１，２，４］トリアゾロ［４，３−ａ］キノキサリン誘導体 |
| ES2855575T3 (es) | 2012-06-26 | 2021-09-23 | Janssen Pharmaceutica Nv | Combinaciones que comprenden compuestos de 4-metil-[1,2,4]triazolo[4,3-a]quinoxalina como inhibidores de PDE2 e inhibidores de PDE10 para su uso en el tratamiento de trastornos neurológicos o metabólicos |
| MX362197B (es) | 2012-07-09 | 2019-01-08 | Janssen Pharmaceutica Nv | Derivados de imidazo[1,2-b]piridazina e imidazo[1,2-a]pirazina como inhibidores de la fosfodiesterasa 10; y el uso de los mismos en el tratamiento de trastornos neurológicos, psiquiátricos y metabólicos. |
| WO2014145192A1 (en) | 2013-03-15 | 2014-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP3666271A1 (en) | 2013-12-03 | 2020-06-17 | Intra-Cellular Therapies, Inc. | Miscrospheres comprising a plga matrix for medical use |
| WO2015089218A1 (en) | 2013-12-10 | 2015-06-18 | David Wustrow | Monocyclic pyrimidine/pyridine compounds as inhibitors of p97 complex |
| US9745300B2 (en) | 2014-04-04 | 2017-08-29 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP2017509686A (ja) | 2014-04-04 | 2017-04-06 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| CN104557922A (zh) * | 2014-12-31 | 2015-04-29 | 定陶县友帮化工有限公司 | 6-溴咪唑并[1,2-a]吡啶-8-甲酸的合成方法 |
| CN109562085A (zh) | 2015-06-12 | 2019-04-02 | 阿速万科学有限责任公司 | 用于预防和治疗rem睡眠行为障碍的二芳基和芳基杂芳基脲衍生物 |
| TW201720439A (zh) | 2015-07-15 | 2017-06-16 | Axovant Sciences Gmbh | 用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物 |
| ES2969145T3 (es) | 2016-01-26 | 2024-05-16 | Intra Cellular Therapies Inc | Derivado de pirido[3',4':4,5]pirrolo[1,2,3-de]quinoxalina para su uso en el tratamiento de trastornos del CNS |
| US10688097B2 (en) | 2016-03-25 | 2020-06-23 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2017172795A1 (en) | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
| WO2018071233A1 (en) | 2016-10-12 | 2018-04-19 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| JP6987868B2 (ja) | 2016-12-29 | 2022-01-05 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
| WO2018126140A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| RU2767410C2 (ru) | 2017-03-24 | 2022-03-17 | Интра-Селлулар Терапиз, Инк. | Новые композиции и способы |
| WO2019060298A1 (en) | 2017-09-19 | 2019-03-28 | Neuroenhancement Lab, LLC | METHOD AND APPARATUS FOR NEURO-ACTIVATION |
| US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
| US11318277B2 (en) | 2017-12-31 | 2022-05-03 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
| US12280219B2 (en) | 2017-12-31 | 2025-04-22 | NeuroLight, Inc. | Method and apparatus for neuroenhancement to enhance emotional response |
| KR102031652B1 (ko) * | 2018-01-19 | 2019-10-14 | 서울대학교산학협력단 | 전이체 단백질 과발현 관련 질환의 양성자방출단층촬영 방사성추적자, 형광영상 진단 및 광역학 치료를 위한 전이체 단백질 표적 리간드 및 이의 제조방법 |
| JP7462568B2 (ja) | 2018-03-23 | 2024-04-05 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
| WO2020047241A1 (en) | 2018-08-29 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
| BR112021003655A2 (pt) | 2018-08-31 | 2021-05-18 | Intra-Cellular Therapies, Inc. | métodos novos |
| WO2020047408A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
| CA3112564A1 (en) | 2018-09-14 | 2020-03-19 | Neuroenhancement Lab, LLC | System and method of improving sleep |
| MX2022000143A (es) | 2019-07-07 | 2022-02-17 | Intra Cellular Therapies Inc | Metodos novedosos. |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
Family Cites Families (151)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1643310A1 (de) | 1966-12-29 | 1971-06-03 | Dow Chemical Co | 4-Alkyl-2,5-dimethoxy-alpha-methyl-phenaethylamin und seine pharmakologisch vertraeglichen Salze |
| US4099012A (en) | 1975-08-28 | 1978-07-04 | Ciba-Geigy Corporation | 2-pyrazolyl-benzophenones |
| DE2926517A1 (de) | 1979-06-30 | 1981-01-15 | Beiersdorf Ag | Substituierte 3-aryl-pyrazole und 5-aryl-isoxazole und verfahren zu ihrer herstellung |
| DE2928485A1 (de) | 1979-07-14 | 1981-01-29 | Bayer Ag | Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen |
| IL61721A (en) | 1980-12-16 | 1984-03-30 | Blank Izhak | Nitroglycerin preparations |
| US4555399A (en) | 1983-11-18 | 1985-11-26 | Key Pharmaceuticals, Inc. | Aspirin tablet |
| US4985352A (en) | 1988-02-29 | 1991-01-15 | The Trustees Of Columbia University In The City Of New York | DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof |
| IT1227626B (it) | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
| CA2022886A1 (en) | 1989-08-08 | 1991-02-09 | Raymond Baker | Substituted pyridines, their preparation, formulations and use in dementia |
| US5661024A (en) | 1989-10-31 | 1997-08-26 | Synaptic Pharmaceutical Corporation | DNA encoding a human serotonic (5-HT2) receptor and uses thereof |
| US5077409A (en) | 1990-05-04 | 1991-12-31 | American Cyanamid Company | Method of preparing bis-aryl amide and urea antagonists of platelet activating factor |
| US5128351A (en) | 1990-05-04 | 1992-07-07 | American Cyanamid Company | Bis-aryl amide and urea antagonists of platelet activating factor |
| US5260303A (en) * | 1991-03-07 | 1993-11-09 | G. D. Searle & Co. | Imidazopyridines as serotonergic 5-HT3 antagonists |
| FR2682379B1 (fr) | 1991-10-09 | 1994-02-11 | Rhone Poulenc Agrochimie | Nouveaux phenylpyrazoles fongicides. |
| FR2690440B1 (fr) | 1992-04-27 | 1995-05-19 | Rhone Poulenc Agrochimie | Arylpyrazoles fongicides. |
| US5905080A (en) | 1993-08-20 | 1999-05-18 | Smithkline Beecham, P.L.C. | Amide and urea derivatives as 5HT1D receptor antagonists |
| FR2722369B1 (fr) | 1994-07-13 | 1998-07-10 | Rhone Poulenc Agrochimie | Compositions fongicides a base de derives 3-phenyl-pyrazoles pour le traitement du materiel vegetal de multiplication, nouveaux derives 3-phenyl-pyrazoles et leurs applications fongicides |
| CA2200981A1 (en) | 1994-10-04 | 1996-04-11 | Hisashi Takasugi | Urea derivatives and their use as acat-inhibitors |
| CA2135253A1 (en) | 1994-11-07 | 1996-05-08 | Michael Dennis | Compound screening based on a window of chemical-messenger-independent activity |
| DK0808312T3 (da) | 1995-02-02 | 2001-02-12 | Smithkline Beecham Plc | Indolderivater som 5-HT-receptorantagonist |
| US6540981B2 (en) | 1997-12-04 | 2003-04-01 | Amersham Health As | Light imaging contrast agents |
| WO1996025157A1 (en) | 1995-02-17 | 1996-08-22 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
| US5856326A (en) | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| AU5658496A (en) | 1995-04-20 | 1996-11-07 | Vectorpharma International S.P.A. | Composite with sodium starch glycolate as a support material and products thereof |
| US5861431A (en) | 1995-06-07 | 1999-01-19 | Iotek, Inc. | Incontinence treatment |
| AU6526896A (en) | 1995-07-22 | 1997-02-18 | Rhone-Poulenc Rorer Limited | Substituted aromatic compounds and their pharmaceutical use |
| US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| US6005008A (en) | 1996-02-16 | 1999-12-21 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
| GB9607219D0 (en) | 1996-04-04 | 1996-06-12 | Smithkline Beecham Plc | Novel compounds |
| JP4073489B2 (ja) | 1996-05-24 | 2008-04-09 | ニューロサーチ・アクティーゼルスカブ | 酸性基を有するフエニル誘導体、その製造方法及びそれをクロライドチャンネル遮断剤として使用する方法 |
| JP2000510862A (ja) | 1996-05-24 | 2000-08-22 | ニューロサーチ・アクティーゼルスカブ | クロライドチャンネル遮断剤として有用なフエニル誘導体 |
| WO1997049286A1 (en) | 1996-06-27 | 1997-12-31 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
| EP0954291B1 (en) | 1996-10-25 | 2005-12-28 | Shire Laboratories Inc. | Soluble form osmotic dose delivery system |
| WO1998024785A1 (en) | 1996-12-02 | 1998-06-11 | Fujisawa Pharmaceutical Co., Ltd. | Indole-urea derivatives with 5-ht antagonist properties |
| US6541209B1 (en) | 1997-04-14 | 2003-04-01 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
| US6420541B1 (en) | 1998-04-14 | 2002-07-16 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
| US6696475B2 (en) | 1997-04-22 | 2004-02-24 | Neurosearch A/S | Substituted phenyl derivatives, their preparation and use |
| PT977741E (pt) | 1997-04-22 | 2004-01-30 | Neurosearch As | Derivados de fenilo substituido, sua preparacao e utilizacao |
| US6028083A (en) | 1997-07-25 | 2000-02-22 | Hoechst Marion Roussel, Inc. | Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol |
| EP1000017A4 (en) | 1997-07-29 | 2000-10-18 | Smithkline Beecham Corp | ANTAGONISTS OF THE IL-8 RECEPTOR |
| KR20010023256A (ko) | 1997-08-27 | 2001-03-26 | 헥살 아게 | 용해도와 생체 이용성이 개선된 신규의 멜록시캄 의약조성물 |
| WO1999023063A1 (en) | 1997-10-31 | 1999-05-14 | Aventis Pharma Limited | Substituted anilides |
| JPH11183942A (ja) | 1997-12-19 | 1999-07-09 | Nippon Mitsubishi Oil Corp | エレクトロクロミック素子 |
| DE69830513T2 (de) | 1997-12-22 | 2006-03-16 | Bayer Pharmaceuticals Corp., West Haven | HEMMUNG DER p38 KINASE UNTER VERWENDUNG VON SYMMETRISCHEN UND ASYMMETRISCHEN DIPHENYLHARNSTOFFEN |
| US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| ES2153809T3 (es) | 1997-12-22 | 2005-07-16 | Bayer Pharmaceuticals Corporation | Inhibicion de la cinasa raf por uso de difnil-ureas sustituidas simetrica y asimetricamente. |
| JP2003514763A (ja) | 1998-04-14 | 2003-04-22 | アリーナ・フアーマシユーチカルズ・インコーポレーテツド | 非内在性の構成的に活性化されるヒトセロトニンレセプターおよびその小分子調節物質 |
| US6140509A (en) | 1998-06-26 | 2000-10-31 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
| GB9816263D0 (en) | 1998-07-24 | 1998-09-23 | Merck Sharp & Dohme | Therapeutic agents |
| US6358698B1 (en) | 1998-10-07 | 2002-03-19 | Acadia Pharmacueticals Inc. | Methods of identifying inverse agonists of the serotonin 2A receptor |
| RU2218328C2 (ru) | 1998-10-22 | 2003-12-10 | НьюроСёрч А/С | Замещенные фенильные производные, их получение и применение |
| US6150393A (en) | 1998-12-18 | 2000-11-21 | Arena Pharmaceuticals, Inc. | Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors |
| US6180138B1 (en) | 1999-01-29 | 2001-01-30 | Abbott Laboratories | Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption |
| DK1173169T3 (da) | 1999-03-26 | 2010-08-23 | Euro Celtique Sa | Arylsubstituerede pyrazoler, imidazoler, oxazoler, thiazoler og pyrroler og anvendelsen deraf |
| GB9909409D0 (en) | 1999-04-24 | 1999-06-23 | Zeneca Ltd | Chemical compounds |
| US6469006B1 (en) | 1999-06-15 | 2002-10-22 | Bristol-Myers Squibb Company | Antiviral indoleoxoacetyl piperazine derivatives |
| IT1312115B1 (it) | 1999-06-24 | 2002-04-04 | Nicox Sa | Composti amorfi e relative composizioni farmaceutiche |
| DE19934433A1 (de) * | 1999-07-22 | 2001-01-25 | Merck Patent Gmbh | N-(Indolcarbonyl-)piperazinderivate |
| HUP0203375A3 (en) | 1999-07-28 | 2005-03-29 | Aventis Pharm Prod Inc | Substituted oxoazaheterocyclyl compounds |
| US6541477B2 (en) | 1999-08-27 | 2003-04-01 | Scios, Inc. | Inhibitors of p38-a kinase |
| WO2001021160A2 (en) | 1999-09-23 | 2001-03-29 | Axxima Pharmaceuticals Aktiengesellschaft | Carboxymide and aniline derivatives as selective inhibitors of pathogens |
| US6531291B1 (en) | 1999-11-10 | 2003-03-11 | The Trustees Of Columbia University In The City Of New York | Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof |
| EP1108720A1 (en) | 1999-12-08 | 2001-06-20 | Basf Aktiengesellschaft | Herbicidal 2-Pyrazolyl-6-Aryloxy-Pyri(mi)dines |
| EP1248770A1 (en) | 1999-12-16 | 2002-10-16 | Biostream Therapeutics | 1,3,4-substituted piperidine analogs and uses thereof in treating addictions |
| MXPA02006137A (es) | 1999-12-20 | 2002-12-05 | Neuromed Tech Inc | Bloqueadores del canal de calcio parcialmente saturados. |
| AU2001241927A1 (en) | 2000-02-28 | 2001-09-12 | Scios Inc. | Inhibitors of p38-alpha kinase |
| FR2810979B1 (fr) | 2000-06-29 | 2002-08-23 | Adir | Nouveaux derives de diphenyluree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| AU2002223492A1 (en) | 2000-11-14 | 2002-05-27 | Neurosearch A/S | Use of malaria parasite anion channel blockers for treating malaria |
| AR035521A1 (es) | 2000-12-22 | 2004-06-02 | Lundbeck & Co As H | Derivados de 3-indolina y composicion farmaceutica que los comprende |
| WO2002076464A1 (en) | 2001-03-22 | 2002-10-03 | Arena Pharmaceuticals, Inc. | Anti-psychosis combination |
| US8889182B2 (en) | 2001-06-29 | 2014-11-18 | Aptalis Pharma Limited | Process of thermodynamical activation of water-insoluble drugs loaded into cross-linked polymers |
| JP4733877B2 (ja) | 2001-08-15 | 2011-07-27 | 富士通セミコンダクター株式会社 | 半導体装置 |
| BRPI0212726B8 (pt) | 2001-09-21 | 2021-05-25 | Bristol Myers Squibb Co | compostos contendo lactamas, e derivados dos mesmos, composição farmacêutica que os compreende e seus usos |
| WO2003062206A2 (en) | 2002-01-23 | 2003-07-31 | Arena Pharmaceuticals, Inc. | Small molecule modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| US6743864B2 (en) | 2002-03-12 | 2004-06-01 | Basell Poliolefine Italia S.P.A. | Polyolefin compositions having high tenacity |
| WO2004034963A2 (en) | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| AU2003259482A1 (en) * | 2002-09-20 | 2004-04-08 | Pfizer Japan Inc. | N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators |
| AU2003275093A1 (en) | 2002-09-24 | 2004-04-19 | Arena Pharmaceuticals, Inc. | Process of making phenylpyrazoles useful as selective 5ht2a modulators and intermediates thereof |
| EP1563631A4 (en) | 2002-11-08 | 2006-08-02 | Interdigital Tech Corp | COMPOSITE CHANNEL QUALITY ESTIMATION TECHNIQUES FOR WIRELESS RECEIVERS |
| AU2003284402A1 (en) | 2002-11-15 | 2004-06-15 | Yamanouchi Pharmaceutical Co., Ltd. | Antagonist to melanin-concentrating hormone receptor |
| US20060229335A1 (en) | 2002-12-24 | 2006-10-12 | Bradley Teegarden | Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a |
| CA2515544A1 (en) | 2003-02-11 | 2004-08-26 | Kemia Inc. | Compounds for the treatment of viral infection |
| JP2006521345A (ja) | 2003-03-28 | 2006-09-21 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | ニコチン性アセチルコリン受容体の正のアロステリック調節剤 |
| GB0309781D0 (en) | 2003-04-29 | 2003-06-04 | Glaxo Group Ltd | Compounds |
| PL1558582T3 (pl) | 2003-07-22 | 2006-05-31 | Arena Pharm Inc | Diarylowe i aryloheteroarylowe pochodne mocznika jako modulatory receptora serotoninowego 5-HT2A użyteczne w profilaktyce i w leczeniu zaburzeń związanych z tym receptorem |
| EP1695966A1 (en) | 2003-07-22 | 2006-08-30 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| EP1653960A4 (en) | 2003-08-13 | 2008-11-26 | Amgen Inc | MELANIN CONCENTRATION HORMONE RECEPTOR ANTAGONIST |
| US7091236B1 (en) | 2003-08-20 | 2006-08-15 | Sciele Pharma, Inc. | Method for increasing the bioavailability of glycopyrrolate |
| US20050054691A1 (en) | 2003-08-29 | 2005-03-10 | St. Jude Children's Research Hospital | Carboxylesterase inhibitors |
| CA2537364A1 (en) | 2003-09-03 | 2005-03-10 | Galapagos Nv | Imidazo[1,5-a]pyridine or imidazo[1,5-a]piperidine derivatives and their use for the preparation of medicament against 5-ht2a receptor-related disorders |
| WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
| US7812176B2 (en) | 2004-03-23 | 2010-10-12 | Arena Pharmaceuticals, Inc. | Processes for preparing substituted N-aryl-N′-[3-(1H-pyrazol-5-YL) phenyl] ureas and intermediates thereof |
| WO2006004722A2 (en) | 2004-06-30 | 2006-01-12 | Biomol Research Laboratories, Inc. | Compositions and methods for selectively activating human sirtuins |
| US20060172992A1 (en) | 2004-08-13 | 2006-08-03 | Eisai Co., Ltd. | Therapeutic agent for overactive bladder resulting from cerebral infarction |
| WO2006018662A2 (en) | 2004-08-16 | 2006-02-23 | Prosidion Limited | Aryl urea derivatives for treating obesity |
| US20060063754A1 (en) | 2004-09-21 | 2006-03-23 | Edgar Dale M | Methods of treating a sleep disorder |
| CA2584485C (en) | 2004-10-20 | 2013-12-31 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| JP2008518014A (ja) | 2004-10-27 | 2008-05-29 | ニューロゲン コーポレイション | Ｃｂ１拮抗薬としてのジアリール尿素 |
| US7563785B2 (en) | 2004-10-29 | 2009-07-21 | Hypnion, Inc. | Quetiapine analogs and methods of use thereof |
| WO2006050165A2 (en) | 2004-11-01 | 2006-05-11 | Seo Hong Yoo | Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
| SA05260357B1 (ar) | 2004-11-19 | 2008-09-08 | ارينا فارماسيتو تيكالز ، أنك | مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به |
| AR051978A1 (es) | 2004-12-01 | 2007-02-21 | Divergence Inc | Composiciones plaguicidas y metodos |
| GB0426313D0 (en) | 2004-12-01 | 2005-01-05 | Merck Sharp & Dohme | Therapeutic agents |
| US20080015223A1 (en) | 2004-12-03 | 2008-01-17 | Arena Pharmaceuticals, Inc. | Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto |
| DE102004061593A1 (de) | 2004-12-21 | 2006-06-22 | Abbott Gmbh & Co. Kg | Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung |
| WO2006070394A1 (en) | 2004-12-28 | 2006-07-06 | Council Of Scientific And Industrial Research | Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors |
| EP1858877B1 (en) | 2005-01-14 | 2014-03-12 | Gilead Connecticut, Inc. | 1,3 substituted diaryl ureas as modulators of kinase activity |
| CA2594563A1 (en) | 2005-01-19 | 2006-07-27 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis or treatment of progressive multifocal leukoencephalopathy |
| AU2006206292B2 (en) | 2005-01-21 | 2009-09-03 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical formulations of zonisamide and methods for their manufacture |
| AR052886A1 (es) | 2005-01-26 | 2007-04-11 | Arena Pharm Inc | Procedimientos para preparar fenilpirazol ureas sustituidas y para la obtencion de sus intermediarios de sintesis |
| BRPI0607088A2 (pt) | 2005-01-27 | 2009-08-04 | Janssen Pharmaceutica Nv | derivados de tetrahidrofurano heterocìclico tetracìclico como inibidores de 5ht2 no tratamento de distúrbios cns |
| GT200600042A (es) * | 2005-02-10 | 2006-09-27 | Aventis Pharma Inc | Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a |
| WO2006089871A2 (en) | 2005-02-23 | 2006-08-31 | Neurosearch A/S | Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias |
| AU2006218403A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
| GB0504828D0 (en) | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
| GB0505437D0 (en) | 2005-03-17 | 2005-04-20 | Merck Sharp & Dohme | Therapeutic agents |
| GB0505725D0 (en) | 2005-03-19 | 2005-04-27 | Merck Sharp & Dohme | Therapeutic agents |
| TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| PT1877390E (pt) | 2005-04-26 | 2010-05-31 | Hypnion Inc | Compostos benzisoxazole-piridina e métodos para a sua utilização |
| EP1734039A1 (en) | 2005-06-13 | 2006-12-20 | Esbatech AG | Aryl urea compounds as BETA-secretase inhibitors |
| CA2613522A1 (en) | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Imidazole based lxr modulators |
| US7754724B2 (en) | 2005-06-30 | 2010-07-13 | Dow Agrosciences Llc | N-substituted piperazines |
| US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US7544685B2 (en) | 2005-08-17 | 2009-06-09 | H. Lundbeck A/S | 2,3-dihydroindole compounds |
| AR055203A1 (es) | 2005-08-31 | 2007-08-08 | Otsuka Pharma Co Ltd | Derivados de benzotiofeno con propiedades antipsicoticas |
| US20090053306A1 (en) | 2005-09-29 | 2009-02-26 | Agarwal Rajesh K | Pharmaceutical Compositions of a 5-HT2A Serotonin Receptor Modulator Useful for the Treatment of Disorders Related Thereto |
| EP2004627A2 (en) | 2006-04-10 | 2008-12-24 | Arena Pharmaceuticals, Inc. | 3-pyridinyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| GB0608655D0 (en) | 2006-05-03 | 2006-06-14 | Merck Sharp & Dohme | Therapeutic Treatment |
| EP3395816A1 (en) | 2006-05-18 | 2018-10-31 | Arena Pharmaceuticals, Inc. | Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| WO2007136875A2 (en) | 2006-05-18 | 2007-11-29 | Arena Pharmaceuticals, Inc. | Acetamide derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| WO2007136703A1 (en) | 2006-05-18 | 2007-11-29 | Arena Pharmaceuticals, Inc. | Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| SG171681A1 (en) | 2006-05-18 | 2011-06-29 | Arena Pharm Inc | Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor |
| JP2010502618A (ja) | 2006-08-31 | 2010-01-28 | アリーナ ファーマシューティカルズ， インコーポレイテッド | セロトニン５−ｈｔ２ａ受容体のモジュレータとしてのベンゾフラン誘導体 |
| TWI415845B (zh) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物 |
| TW200823204A (en) | 2006-10-17 | 2008-06-01 | Arena Pharm Inc | Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto |
| WO2008054748A2 (en) | 2006-10-31 | 2008-05-08 | Arena Pharmaceuticals, Inc. | Indazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| US9034890B2 (en) | 2006-11-15 | 2015-05-19 | Steven A. Rich | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases |
| US8969402B2 (en) | 2006-11-15 | 2015-03-03 | Steven A. Rich | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases |
| US8097633B2 (en) | 2006-11-15 | 2012-01-17 | Rich Steven A | Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium |
| JP5399262B2 (ja) | 2006-12-08 | 2014-01-29 | エグゼリクシス パテント カンパニー エルエルシー | Ｌｘｒおよびｆｘｒのモジュレーター |
| ES2421237T7 (es) | 2007-08-15 | 2013-09-30 | Arena Pharmaceuticals, Inc. | Derivados de imidazo[1,2-a]piridin como moduladores del receptor serotoninérgico 5ht2a en el tratamiento de trastornos relacionados con el mismo |
| NO2200610T3 (enExample) | 2007-09-21 | 2018-06-09 | ||
| EP2508177A1 (en) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
| WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
| SMT201800199T1 (it) | 2008-10-28 | 2018-05-02 | Arena Pharm Inc | Composizioni di un modulatore dei recettori della serotonina 5-ht2a utili per il trattamento di disturbi correlati a esso |
| GB201111712D0 (en) | 2011-07-08 | 2011-08-24 | Gosforth Ct Holdings Pty Ltd | Pharmaceutical compositions |
| NZ702730A (en) | 2012-06-11 | 2017-08-25 | Psychogenics Inc | Treatment of motor and movement disorder side effects associated with parkinson’s disease treatments |
| JOP20210047A1 (ar) | 2012-10-25 | 2017-06-16 | Otsuka Pharma Co Ltd | عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه |
| US9446037B2 (en) | 2012-11-27 | 2016-09-20 | Acadia Pharmaceuticals Inc. | Methods for the treatment of parkinson's disease psychosis using pimavanserin |
| KR101472682B1 (ko) | 2013-07-23 | 2014-12-15 | 고려대학교 산학협력단 | 메타물질 제조 방법, 이에 의해 제조된 메타물질 구조 필름 및 이를 이용한 광학 이미징 시스템 |
-
2008
- 2008-08-14 ES ES08795334T patent/ES2421237T7/es active Active
- 2008-08-14 WO PCT/US2008/009740 patent/WO2009023253A2/en not_active Ceased
- 2008-08-14 JP JP2010521039A patent/JP5393677B2/ja not_active Expired - Fee Related
- 2008-08-14 EP EP08795334.5A patent/EP2190844B3/en active Active
- 2008-08-14 US US12/673,463 patent/US9567327B2/en active Active
-
2017
- 2017-01-06 US US15/400,670 patent/US10058549B2/en active Active
-
2018
- 2018-08-13 US US16/101,896 patent/US20190142826A1/en not_active Abandoned
-
2020
- 2020-09-09 US US17/015,358 patent/US20210128552A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010536757A5 (enExample) | ||
| CN103251579B (zh) | 取代的n-酰基苯胺及其使用方法 | |
| TWI666202B (zh) | 作為ｍＩＤＨ１抑制劑之苯并咪唑－２－胺 | |
| JP6434482B2 (ja) | 置換アシルアニリドおよびそれらの使用方法 | |
| CN104066731B (zh) | 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类 | |
| JP2012501327A5 (enExample) | ||
| US20070265296A1 (en) | Nuclear receptor binding agents | |
| JP2020519589A5 (enExample) | ||
| JP2017527604A5 (enExample) | ||
| CN107223125A (zh) | sGC刺激剂 | |
| JP2017025113A (ja) | Ｗｎｔシグナル経路のインダゾール阻害剤およびその治療的使用 | |
| EA032028B1 (ru) | СТИМУЛЯТОРЫ рГЦ | |
| JP2013544893A5 (enExample) | ||
| ME01312B (me) | Heteroaril supstituirani pirol0[2,3-b]piridini i pirol0 [ 2,3-b]pirimidini kao inhibitori janus kinaze | |
| JP6849618B2 (ja) | 中性エンドペプチダーゼの阻害剤（ＮＥＰ阻害剤）および／またはアンジオテンシンＩＩ拮抗薬と組み合わせた可溶性グアニル酸シクラーゼ（ｓＧＣ）の刺激薬および／または活性化薬ならびにその使用 | |
| JP2017517538A5 (enExample) | ||
| TWI823903B (zh) | sGC刺激劑之晶型 | |
| JP7667764B2 (ja) | 線維症疾患の治療及び／又は予防用アミノナフトキノン化合物 | |
| US8637706B2 (en) | Nuclear receptor binding agents | |
| JP7016853B2 (ja) | ｓＧＣ刺激剤のリンプロドラッグ | |
| KR20190025989A (ko) | sGC 자극제의 고체 형태 | |
| US20040097539A1 (en) | Hsp inductor | |
| JP2008519815A5 (enExample) | ||
| KR20240058047A (ko) | sGC 자극제 | |
| JP2010538078A (ja) | 線維症を治療するためのピペリジニルアミノ−チエノ［２，３−ｄ］ピリミジン化合物 |